Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis

Arno Verleye; Veerle Wijtvliet; Steven Abrams; Rachel Hellemans; Rania Bougrea; Annick Massart; Lissa Pipeleers; Karl Martin Wissing; Kevin K Ariën; Benedicte Y De Winter; Pierre Van Damme; Daniel Abramowicz; Kristien J Ledeganck

doi:10.1093/ndt/gfac174

Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis

Arno Verleye, Veerle Wijtvliet, Steven Abrams, Rachel Hellemans, Rania Bougrea, Annick Massart, Lissa Pipeleers, Karl Martin Wissing, Kevin K Ariën, Benedicte Y De Winter, Pierre Van Damme, Daniel Abramowicz, Kristien J Ledeganck

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

BACKGROUND: In the general population, the seroconversion rate after primary vaccination with two doses of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA (mRNA) vaccine reaches nearly 100%, with significantly higher antibody titers after mRNA-1273 vaccination compared to BNT162b2 vaccination. Here we performed a systematic review and meta-analysis to compare the antibody response after two-dose mRNA-1273 versus BNT162b2 vaccination in solid organ transplant (SOT) recipients.

METHODS: A systematic literature review was performed using PubMed, Web of Science and the Cochrane Library and original research papers were included for a meta-analysis to calculate vaccine-specific seroconversion rates for each of the mRNA vaccines. Next, the pooled relative seroconversion rate was estimated.

RESULTS: Eight studies that described the development of antibodies against receptor-binding domain (RBD) and/or spike protein were eligible for meta-analysis. Two of these studies also reported antibody titers. The meta-analysis revealed lower seroconversion rates in SOT recipients vaccinated with two doses of BNT162b2 {44.3% [95% confidence interval (CI) 34.1-54.7]} as compared with patients vaccinated with two doses of mRNA-1273 [58.4% (95% CI 47.2-69.2)]. The relative seroconversion rate was 0.795 (95% CI 0.732-0.864).

CONCLUSIONS: This systematic review and meta-analysis indicates that in SOT recipients, higher seroconversion rates were observed after vaccination with mRNA-1273 compared with BNT162b2.

Original language	English
Pages (from-to)	1566-1575
Number of pages	10
Journal	Nephrology Dialysis Transplantation
Volume	37
Issue number	8
Early online date	2022
DOIs	https://doi.org/10.1093/ndt/gfac174
Publication status	Published - 26 Jul 2022

Bibliographical note

Keywords

SARS-CoV-2/COVID-19
antibody response
mRNA vaccines
meta-analysis
solid organ transplant recipients

Access to Document

10.1093/ndt/gfac174

Cite this

Verleye, A., Wijtvliet, V., Abrams, S., Hellemans, R., Bougrea, R., Massart, A., Pipeleers, L., Wissing, K. M., Ariën, K. K., De Winter, B. Y., Van Damme, P., Abramowicz, D., & Ledeganck, K. J. (2022). Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 37(8), 1566-1575. https://doi.org/10.1093/ndt/gfac174

Verleye, Arno ; Wijtvliet, Veerle ; Abrams, Steven ; Hellemans, Rachel ; Bougrea, Rania ; Massart, Annick ; Pipeleers, Lissa ; Wissing, Karl Martin ; Ariën, Kevin K ; De Winter, Benedicte Y ; Van Damme, Pierre ; Abramowicz, Daniel ; Ledeganck, Kristien J. / Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients : a systematic review and meta-analysis. In: Nephrology Dialysis Transplantation. 2022 ; Vol. 37, No. 8. pp. 1566-1575.

@article{0753caee01dd404b8f84de6d540c572a,

title = "Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis",

abstract = "BACKGROUND: In the general population, the seroconversion rate after primary vaccination with two doses of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA (mRNA) vaccine reaches nearly 100%, with significantly higher antibody titers after mRNA-1273 vaccination compared to BNT162b2 vaccination. Here we performed a systematic review and meta-analysis to compare the antibody response after two-dose mRNA-1273 versus BNT162b2 vaccination in solid organ transplant (SOT) recipients.METHODS: A systematic literature review was performed using PubMed, Web of Science and the Cochrane Library and original research papers were included for a meta-analysis to calculate vaccine-specific seroconversion rates for each of the mRNA vaccines. Next, the pooled relative seroconversion rate was estimated.RESULTS: Eight studies that described the development of antibodies against receptor-binding domain (RBD) and/or spike protein were eligible for meta-analysis. Two of these studies also reported antibody titers. The meta-analysis revealed lower seroconversion rates in SOT recipients vaccinated with two doses of BNT162b2 {44.3% [95% confidence interval (CI) 34.1-54.7]} as compared with patients vaccinated with two doses of mRNA-1273 [58.4% (95% CI 47.2-69.2)]. The relative seroconversion rate was 0.795 (95% CI 0.732-0.864).CONCLUSIONS: This systematic review and meta-analysis indicates that in SOT recipients, higher seroconversion rates were observed after vaccination with mRNA-1273 compared with BNT162b2.",

keywords = "SARS-CoV-2/COVID-19, antibody response, mRNA vaccines, meta-analysis, solid organ transplant recipients",

author = "Arno Verleye and Veerle Wijtvliet and Steven Abrams and Rachel Hellemans and Rania Bougrea and Annick Massart and Lissa Pipeleers and Wissing, {Karl Martin} and Ari{\"e}n, {Kevin K} and {De Winter}, {Benedicte Y} and {Van Damme}, Pierre and Daniel Abramowicz and Ledeganck, {Kristien J}",

note = "{\textcopyright} The Author(s) 2022. Published by Oxford University Press on behalf of the ERA.",

year = "2022",

month = jul,

day = "26",

doi = "10.1093/ndt/gfac174",

language = "English",

volume = "37",

pages = "1566--1575",

journal = "Nephrology Dialysis Transplantation",

issn = "0931-0509",

publisher = "Oxford University Press",

number = "8",

}

Verleye, A, Wijtvliet, V, Abrams, S, Hellemans, R, Bougrea, R, Massart, A, Pipeleers, L , Wissing, KM, Ariën, KK, De Winter, BY, Van Damme, P, Abramowicz, D & Ledeganck, KJ 2022, 'Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis', Nephrology Dialysis Transplantation, vol. 37, no. 8, pp. 1566-1575. https://doi.org/10.1093/ndt/gfac174

Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients : a systematic review and meta-analysis. / Verleye, Arno; Wijtvliet, Veerle; Abrams, Steven; Hellemans, Rachel; Bougrea, Rania; Massart, Annick; Pipeleers, Lissa ; Wissing, Karl Martin; Ariën, Kevin K; De Winter, Benedicte Y; Van Damme, Pierre; Abramowicz, Daniel; Ledeganck, Kristien J.

In: Nephrology Dialysis Transplantation, Vol. 37, No. 8, 26.07.2022, p. 1566-1575.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients

T2 - a systematic review and meta-analysis

AU - Verleye, Arno

AU - Wijtvliet, Veerle

AU - Abrams, Steven

AU - Hellemans, Rachel

AU - Bougrea, Rania

AU - Massart, Annick

AU - Pipeleers, Lissa

AU - Wissing, Karl Martin

AU - Ariën, Kevin K

AU - De Winter, Benedicte Y

AU - Van Damme, Pierre

AU - Abramowicz, Daniel

AU - Ledeganck, Kristien J

PY - 2022/7/26

Y1 - 2022/7/26

N2 - BACKGROUND: In the general population, the seroconversion rate after primary vaccination with two doses of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA (mRNA) vaccine reaches nearly 100%, with significantly higher antibody titers after mRNA-1273 vaccination compared to BNT162b2 vaccination. Here we performed a systematic review and meta-analysis to compare the antibody response after two-dose mRNA-1273 versus BNT162b2 vaccination in solid organ transplant (SOT) recipients.METHODS: A systematic literature review was performed using PubMed, Web of Science and the Cochrane Library and original research papers were included for a meta-analysis to calculate vaccine-specific seroconversion rates for each of the mRNA vaccines. Next, the pooled relative seroconversion rate was estimated.RESULTS: Eight studies that described the development of antibodies against receptor-binding domain (RBD) and/or spike protein were eligible for meta-analysis. Two of these studies also reported antibody titers. The meta-analysis revealed lower seroconversion rates in SOT recipients vaccinated with two doses of BNT162b2 {44.3% [95% confidence interval (CI) 34.1-54.7]} as compared with patients vaccinated with two doses of mRNA-1273 [58.4% (95% CI 47.2-69.2)]. The relative seroconversion rate was 0.795 (95% CI 0.732-0.864).CONCLUSIONS: This systematic review and meta-analysis indicates that in SOT recipients, higher seroconversion rates were observed after vaccination with mRNA-1273 compared with BNT162b2.

AB - BACKGROUND: In the general population, the seroconversion rate after primary vaccination with two doses of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA (mRNA) vaccine reaches nearly 100%, with significantly higher antibody titers after mRNA-1273 vaccination compared to BNT162b2 vaccination. Here we performed a systematic review and meta-analysis to compare the antibody response after two-dose mRNA-1273 versus BNT162b2 vaccination in solid organ transplant (SOT) recipients.METHODS: A systematic literature review was performed using PubMed, Web of Science and the Cochrane Library and original research papers were included for a meta-analysis to calculate vaccine-specific seroconversion rates for each of the mRNA vaccines. Next, the pooled relative seroconversion rate was estimated.RESULTS: Eight studies that described the development of antibodies against receptor-binding domain (RBD) and/or spike protein were eligible for meta-analysis. Two of these studies also reported antibody titers. The meta-analysis revealed lower seroconversion rates in SOT recipients vaccinated with two doses of BNT162b2 {44.3% [95% confidence interval (CI) 34.1-54.7]} as compared with patients vaccinated with two doses of mRNA-1273 [58.4% (95% CI 47.2-69.2)]. The relative seroconversion rate was 0.795 (95% CI 0.732-0.864).CONCLUSIONS: This systematic review and meta-analysis indicates that in SOT recipients, higher seroconversion rates were observed after vaccination with mRNA-1273 compared with BNT162b2.

KW - SARS-CoV-2/COVID-19

KW - antibody response

KW - mRNA vaccines

KW - meta-analysis

KW - solid organ transplant recipients

UR - http://www.scopus.com/inward/record.url?scp=85135382556&partnerID=8YFLogxK

U2 - 10.1093/ndt/gfac174

DO - 10.1093/ndt/gfac174

M3 - Article

C2 - 35544087

VL - 37

SP - 1566

EP - 1575

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 8

ER -

Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this